News
IPA
1.220
-2.40%
-0.030
Weekly Report: what happened at IPA last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at IPA last week (0408-0412)?
Weekly Report · 04/15 10:58
Weekly Report: what happened at IPA last week (0401-0405)?
Weekly Report · 04/08 11:02
Weekly Report: what happened at IPA last week (0325-0329)?
Weekly Report · 04/01 11:01
IPA and InterSystems Partner for AI-Driven Healthcare
TipRanks · 03/28 18:28
IPA and InterSystems Forge AI Healthcare Breakthrough
TipRanks · 03/28 11:37
EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications
Immunoprecise Antibodies and InterSystems have collaborated to integrate the new vector search capability of the IRIS and LENSai platforms for AI-driven applications in healthcare and life sciences. The global AI market is forecasted to surpass $1.3 trillion by 2032.
Benzinga · 03/28 10:45
Weekly Report: what happened at IPA last week (0318-0322)?
Weekly Report · 03/25 11:03
IPA Boosts AI Drug Discovery with Strategic Acquisition
TipRanks · 03/20 16:57
IPA Enhances Drug Discovery with Carterra LSA
TipRanks · 03/20 11:37
ImmunoPrecise Antibodies acquires Carterra LSA instrument
Healthcare M&A ImmunoPrecise Antibodies acquires Carterra LSA instrument. IPA +2.75% premarket to $1.49. The instrument allows for high throughput surface plasmon resonance-based antibody characterizations. Immuno precise antibodies Ltd. (IPA)
Seeking Alpha · 03/20 11:36
Press Release: IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments. Significant throughput of LSA to advance IPA's diversity- and data-driven drug development and to enrich LENSai(TM) IPA is an artificial intelligence-driven research and technology company.
Dow Jones · 03/20 11:02
Weekly Report: what happened at IPA last week (0311-0315)?
Weekly Report · 03/18 11:02
ImmunoPrecise Antibodies Price Target Maintained With a $5.00/Share by Benchmark
Dow Jones · 03/15 14:09
Benchmark Reiterates Speculative Buy on ImmunoPrecise Antibodies, Maintains $5 Price Target
Benzinga · 03/15 14:00
ImmunoPrecise Antibodies Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 13:34
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
Benzinga · 03/15 13:24
Buy Rating Affirmed: ImmunoPrecise Antibodies’ Growth and Innovation Drive Positive Outlook
TipRanks · 03/15 10:15
IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024
ImmunoPrecise Antibodies reported earnings per share of -8 cents. The company reported revenue of $4.56 million. This was 1.22% better than the analyst estimate for revenue of -7 cents. The company also reported quarterly results.
Investorplace · 03/14 16:52
Immunoprecise Antibodies Ltd reports results for the quarter ended in January - Earnings Summary
Immunoprecise Antibodies Ltd reports results for the quarter ended in January. Revenue rose 20.3% to C$6.22 million from a year ago. The company reported a quarterly adjusted loss of 11 cents per share. Wall Street expected a loss of 10 cents.
Reuters · 03/14 14:25
More
Webull provides a variety of real-time IPA stock news. You can receive the latest news about Immunoprecise through multiple platforms. This information may help you make smarter investment decisions.
About IPA
ImmunoPrecise Antibodies Ltd. is a Canada-based full-service, therapeutic antibody discovery company. The Company offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. It leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. It offers a selection of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The Company offers support to its partners, including rapid multi-omic analysis, customized project design, target identification and preparation, an on-site vivarium, and others.